Emile Barrow
Cardiovascular Disease · Monroe, LANPI 1205820255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 339 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,783 and has fallen 98.8% since, to $22 in 2022.
Across 339 payments — averaging $13.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$810
- Johnson & Johnson$701
- Amgen$558
- Kowa Pharmaceuticals America, Inc.$394
- Sanofi-aventis U.S. LLC$394
- Pfizer$341
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,660100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 63 | $810 |
| Johnson & Johnson | 58 | $701 |
| Amgen | 60 | $558 |
| Kowa Pharmaceuticals America, Inc. | 23 | $394 |
| Sanofi-aventis U.S. LLC | 26 | $394 |
| Pfizer | 24 | $341 |
| Amarin Pharma, Inc. | 17 | $268 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $264 |
| Abbott | 3 | $228 |
| Actelion Pharmaceuticals US, Inc. | 7 | $116 |
| Boehringer Ingelheim | 8 | $116 |
| AstraZeneca | 8 | $110 |
| E.r. Squibb & Sons, L.L.C. | 8 | $108 |
| Regeneron Healthcare Solutions, Inc. | 5 | $83 |
| Medtronic(2 entities) | 3 | $43 |
| Merck | 2 | $34 |
| Bayer | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,660 in reported general payments places this provider in the 55th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Monroe
- Imran ChaudryMonroe$202K
- Mazen IqbalMonroe$82K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Darrell SoletMorgan City$81K
- Ghiath MikdadiHammond$76K
- Samuel StaggHouma$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.